SEMA4D and breast cancer: The Semaphorin 4D (SEMA4D) has significantly higher positive expressions in cisplatin‐resistant epithelial ovarian cancer (CREOC) tissues with Bevacizumab‐containing chemotherapy (BC) response than in the BC nonresponse group, providing a novel therapeutic strategy and mechanism study for cisplatin‐resistant epithelial ovarian cancer (EOC) [15].